Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Slc1a5em1/Cya
Common Name:
Slc1a5-KO
Product ID:
S-KO-04358
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Slc1a5-KO
Strain ID
KOCMP-20514-Slc1a5-B6J-VA
Gene Name
Slc1a5
Product ID
S-KO-04358
Gene Alias
AAAT; ASCT2; ATBO; M7V1; M7VS1; R16; RDRC; Slc1a7
Background
C57BL/6JCya
NCBI ID
20514
Modification
Conventional knockout
Chromosome
7
Phenotype
MGI:105305
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Slc1a5em1/Cya mice (Catalog S-KO-04358) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000108496
NCBI RefSeq
NM_009201
Target Region
Exon 3~8
Size of Effective Region
~9.8 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Slc1a5, also known as alanine-serine-cysteine transporter 2 (ASCT2), is a crucial neutral amino-acid exchanger and the most well-studied glutamine transporter [8]. Glutamine is an essential nutrient regulating energy production, redox homeostasis, and signaling. Slc1a5 is involved in processes like mitochondrial metabolism, amino-acid sensing, and activation of mTORC1, a key metabolic regulator [2,5].

In osteoclastogenesis, Slc1a5-deficient mice showed reduced glutamine uptake in bone marrow cells stimulated with RANKL. The formation of multinucleated osteoclasts was severely impaired in Slc1a5-/-bone marrow cells, and the expression of ERK, NFκB, p70S6K, and NFATc1 was suppressed, indicating its important role in osteoclast formation [8]. In cancer, a SLC1A5 variant was found to transport glutamine into mitochondria, mediating cancer metabolic reprogramming. Overexpression of this variant conferred gemcitabine resistance to pancreatic cancer cells, and its knockdown and overexpression altered cancer cell and tumor growth [1]. In melanoma, miR-137 negatively regulated ferroptosis by directly targeting SLC1A5, with miR-137 knockdown enhancing the antitumor activity of erastin both in vitro and in vivo [3]. In gastric cancer, quercetin induced ferroptosis by targeting SLC1A5, inhibiting the NRF2/xCT pathway, activating the p-Camk2/p-DRP1 pathway, and accelerating iron deposition [4]. In leukemia, the STAT3-MYC axis regulated SLC1A5, and inhibition of SLC1A5 reduced intracellular levels of glutamine, glutathione, and multiple TCA cycle metabolites, leading to reduced TCA cycle activity and inhibition of OXPHOS in leukemia stem cells [5]. In glioma, SLC1A5 knockdown inhibited cell proliferation, invasion, and reduced ferroptosis sensitivity via the GPX4-dependent pathway, and was related to immune response [6]. In hepatocellular carcinoma, lncRNA SLC1A5-AS regulated SLC1A5 expression, and overexpression of SLC1A5-AS increased ASCT2 levels, enhancing glutamine uptake and promoting HCC cell growth and metastasis [7]. In pancreatic adenocarcinoma, SLC1A5 overexpression promoted cancer cell proliferation, migration, and invasion, and was related to a poor prognosis and suppressed antitumor immune process [9]. In hepatocellular carcinoma, elevated SLC1A5 was associated with poor prognosis and resistance to transarterial chemoembolization, and SLC1A5 may mediate cell migration and drug resistance via the EMT pathway [10].

In conclusion, Slc1a5 plays essential roles in various biological processes, especially in osteoclast formation and cancer-related metabolism, ferroptosis, and immune-related processes. The use of gene-knockout models, such as the Slc1a5-deficient mice, has significantly contributed to understanding its functions in osteoclastogenesis. In the context of cancer, studies on SLC1A5 have provided insights into its role in metabolic reprogramming, ferroptosis regulation, and immune-tumor interactions, suggesting potential therapeutic targets for multiple cancers.

References:

1. Yoo, Hee Chan, Park, Seung Joon, Nam, Miso, Bang, Seungmin, Han, Jung Min. 2019. A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells. In Cell metabolism, 31, 267-283.e12. doi:10.1016/j.cmet.2019.11.020. https://pubmed.ncbi.nlm.nih.gov/31866442/

2. Nachef, Marianna, Ali, Alaa Kassim, Almutairi, Saeedah Musaed, Lee, Seung-Hwan. 2021. Targeting SLC1A5 and SLC3A2/SLC7A5 as a Potential Strategy to Strengthen Anti-Tumor Immunity in the Tumor Microenvironment. In Frontiers in immunology, 12, 624324. doi:10.3389/fimmu.2021.624324. https://pubmed.ncbi.nlm.nih.gov/33953707/

3. Luo, Meiying, Wu, Longfei, Zhang, Kexin, Ren, Wenyan, Yang, Yongfei. 2018. miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. In Cell death and differentiation, 25, 1457-1472. doi:10.1038/s41418-017-0053-8. https://pubmed.ncbi.nlm.nih.gov/29348676/

4. Ding, Lixian, Dang, Shuwei, Sun, Mingjun, Li, Jinxing, Li, Guodong. 2024. Quercetin induces ferroptosis in gastric cancer cells by targeting SLC1A5 and regulating the p-Camk2/p-DRP1 and NRF2/GPX4 Axes. In Free radical biology & medicine, 213, 150-163. doi:10.1016/j.freeradbiomed.2024.01.002. https://pubmed.ncbi.nlm.nih.gov/38190923/

5. Amaya, Maria L, Inguva, Anagha, Pei, Shanshan, Reigan, Philip, Jordan, Craig T. . The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. In Blood, 139, 584-596. doi:10.1182/blood.2021013201. https://pubmed.ncbi.nlm.nih.gov/34525179/

6. Han, Liying, Zhou, Jinpeng, Li, Leiyang, Wang, Liang, Qu, Yan. 2022. SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma. In Cell death & disease, 13, 1071. doi:10.1038/s41419-022-05526-w. https://pubmed.ncbi.nlm.nih.gov/36566214/

7. Jiang, Jiawen, Dong, Wei, Zhang, Wen, Wang, Jiao, Li, Zhe. . LncRNA SLC1A5-AS/MZF1/ASCT2 Axis Contributes to Malignant Progression of Hepatocellular Carcinoma. In Discovery medicine, 35, 995-1014. doi:10.24976/Discov.Med.202335179.96. https://pubmed.ncbi.nlm.nih.gov/38058065/

8. Tsumura, Hideki, Shindo, Miyuki, Ito, Morihiro, Umezawa, Akihiro, Ito, Yasuhiko. 2021. Relationships between Slc1a5 and Osteoclastogenesis. In Comparative medicine, 71, 285-294. doi:10.30802/AALAS-CM-21-000012. https://pubmed.ncbi.nlm.nih.gov/34301346/

9. Xu, Fangshi, Wang, Hai, Pei, Honghong, Wang, Shuang, Ren, Bin-Cheng. 2022. SLC1A5 Prefers to Play as an Accomplice Rather Than an Opponent in Pancreatic Adenocarcinoma. In Frontiers in cell and developmental biology, 10, 800925. doi:10.3389/fcell.2022.800925. https://pubmed.ncbi.nlm.nih.gov/35419359/

10. Zhang, Guixiong, Xiao, Yitai, Tan, Jizhou, Fan, Wenzhe, Li, Jiaping. 2024. Elevated SLC1A5 associated with poor prognosis and therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma. In Journal of translational medicine, 22, 543. doi:10.1186/s12967-024-05298-1. https://pubmed.ncbi.nlm.nih.gov/38844930/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest